Australia's largest stock trading and investment forum Australia's #1 stock forum

GMV

Click for more information

0.00%

3.9¢ g medical innovations holdings limited

GMV The Future, page-9

First 9 Last

Share
Profile

Follow
more4less

1,991 Posts.

875

14/06/19

14:14

Post #: 39062599
Share

Originally posted by Glyco ↑

$100 billion medtech market in china; was U$56 billions in 2016, cagr +20%pa)
Primza will have first mover advantage in china;
hello there Irtc & Beat, see you around.

/
China’s Healthcare Reforms Underscore Market Growth

February 19, 2018 Posted by China Briefing

By Dezan Shira & Associates
Editor: Qian Zhou
Due to its size and growth potential, China’s healthcare market is one of the most attractive in the world for foreign investors. China surpassed Japan to become the world’s second-largest healthcare market in 2013 and continues to develop at double-digit rates. Indeed, it’s the fastest-growing healthcare market of all large emerging economies.
Recently in 2016, China’s healthcare market reached RMB 5,670.3 billion (US$853.7 billion), an increase of 12 percent in local currency when compared with that of 2015.

Among others, the medical device market grew 20.1 percent to RMB 370 billion (US$56 billion) in 2016, while pharmaceutical and health products sales reached RMB 1,839 billion (US$277 billion), up 10.4 percent year-on-year.

Yet, the Chinese healthcare market is still relatively immature. Although healthcare expenditures in the country has increased more than four-fold – from RMB 1,096.6 billion (US$126.1 billion) in 2006 to RMB 4,634.5 billion (US$697.7 billion) in 2016 – healthcare spending per capita is only around six percent of its GDP..

/

This compares unfavorably with the 17 percent in the US, 10 percent in Japan and Europe, and the average nine percent in OECD countries. By 2020, China’s healthcare spending is expected to account for 6.5 to 7 percent of its total GDP, which is around US$1 trillion.

And by 2030, China’s healthcare market is targeted to reach RMB 16,000 billion (around US$2 trillion), as it is stipulated in the Plan of Health China 2030 released by the State Council in October 2016. Every health sector – from pharmaceuticals to medical devices – will have more opportunities.

While many market factors are positive, foreign investors must study the rapidly-changing regulatory environment for the industry. Healthcare reform in China started in 2009 and is still ongoing, often with different goals each year.
We summarize the major 2017 reforms below...
https://www.china-briefing.com/news/healthcare-reforms-underscore-market-growth-china/

Expand

Our 2 markets where we will flourish will be the USA and China for our products and both just happen to be dual listing for the company.

I'm expecting the China numbers to be very impressive when it starts selling there. Year on year growth minimum and I know a lot of work behind the scenes has been done getting ready to launch there.

GMV employed logistic specialist Manager last month to handle the e commerce side, distribution and inventory side of the business.

The green channel comes into play at this stage of submission

NASDAQ road show finishes this weekend and hearing that Yacov is very happy with the outcome, so cannot wait for the update on this.

AGM following week and then the process of the HK listing leading up to the end of the Year.

Last edited by more4less: 14/06/19

GMV Price at posting: 21.5¢ Sentiment: None Disclosure: Not Held
20 Upvote

0 Great analysis

Reply

Top Stories

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

RCE

Recce's R327 found effective against E.coli during clinical trial

Microcap Wrap: 5 explorers with news out today

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

There are more pages in this discussion • 3,005 more messages in this thread...

First 9 Last

Add GMV (ASX) to my watchlist

SPONSORED BY